Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.53 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.53 |
| ▸ | CDC42 | P60953 | 1/20 | 0.53 |
| ▸ | RAC1 | P63000 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9037513 | 0.81 | PTGS2 (0.55) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL28282836 | 0.79 | PTGS2 (0.57) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL31512445 | 0.79 | PTGS2 (0.61) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL491187 | 0.79 | PTGS2 (0.61) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL6372641 | 0.79 | PTGS2 (0.57) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL3051005 | 0.78 | PTGS2 (0.40) | PTGS2PTGS1TSHR | |
| SCHEMBL30946604 | 0.76 | PTGS2 (0.57) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL490635 | 0.76 | PTGS2 (0.57) | PTGS2AKR1C3AKR1C2PTGS1CDC42 | |
| SCHEMBL7073236 | 0.76 | SMN1; SMN2 (0.54) | AKR1C3AKR1C2POLBHSD17B10 | |
| SCHEMBL7960349 | 0.76 | PTGS2 (0.57) | PTGS2AKR1C3AKR1C2PTGS1CDC42 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | PTGS2 2169/4885AKR1C3 425/4885AKR1C2 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.